Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Liabilities and Shareholders Equity (2017 - 2021)

Historic Liabilities and Shareholders Equity for Cogent Biosciences (COGT) over the last 5 years, with Q3 2021 value amounting to $215.4 million.

  • Cogent Biosciences' Liabilities and Shareholders Equity rose 5398.94% to $215.4 million in Q3 2021 from the same period last year, while for Dec 2021 it was $681.5 million, marking a year-over-year increase of 4790.38%. This contributed to the annual value of $250.9 million for FY2020, which is 40769.08% up from last year.
  • Per Cogent Biosciences' latest filing, its Liabilities and Shareholders Equity stood at $215.4 million for Q3 2021, which was up 5398.94% from $228.5 million recorded in Q2 2021.
  • Over the past 5 years, Cogent Biosciences' Liabilities and Shareholders Equity peaked at $250.9 million during Q4 2020, and registered a low of $31.1 million during Q2 2020.
  • For the 5-year period, Cogent Biosciences' Liabilities and Shareholders Equity averaged around $111.0 million, with its median value being $83.6 million (2018).
  • As far as peak fluctuations go, Cogent Biosciences' Liabilities and Shareholders Equity tumbled by 5519.28% in 2020, and later surged by 63584.29% in 2021.
  • Over the past 5 years, Cogent Biosciences' Liabilities and Shareholders Equity (Quarter) stood at $49.1 million in 2017, then surged by 74.95% to $85.9 million in 2018, then crashed by 42.48% to $49.4 million in 2019, then surged by 407.69% to $250.9 million in 2020, then fell by 14.16% to $215.4 million in 2021.
  • Its last three reported values are $215.4 million in Q3 2021, $228.5 million for Q2 2021, and $237.6 million during Q1 2021.